No Data
Insiders the Biggest Winners as Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Market Cap Rises to CN¥8.8b
Ruipu Biotech: Report for the first quarter of 2025
Tianjin Ringpu Bio-Technology (300119.SZ) has released its first-quarter performance, with a net income of 0.116 billion yuan, an increase of 28.45%.
Tianjin Ringpu Bio-Technology (300119.SZ) released its first quarter report for 2025, and the company generated revenue of 8.22...
Huachuang Securities: In the first quarter, the issuance of vaccine batches increased significantly, and the price of macrocyclic lactone veterinary medicine Active Pharmaceutical Ingredients continues to rise.
The demand for animal health products is gradually recovering, and by 2025, the breeding sector is expected to maintain profitability. The continuity of demand for animal health products may be ensured, and the Operation in the animal health Sector is gradually establishing a turning point.
Tianjin Ringpu Bio-Technology (300119.SZ): Obtained approval number for veterinary drug products.
Gelonghui, April 16 - Tianjin Ringpu Bio-Technology (300119.SZ) announced that its wholly-owned subsidiary, Ringpu (Tianjin) Biopharmaceutical Co., Ltd., has passed the national comparison number evaluation review for its cat deworming drug and has recently obtained the veterinary drug product approval number issued by the Ministry of Agriculture and Rural Affairs. Milbemycin oxime and praziquantel tablets (for cats) is a broad-spectrum, highly effective compound internal parasitic drug that can simultaneously kill various common parasites in pet cats, such as tapeworms, roundworms, and hookworms. It has four core advantages: broad-spectrum deworming, safety and reliability, convenience and ease of use, and long-lasting protection. This product relies on the company's cutting-edge R&D platform and strictly adheres to veterinary drug R&D regulations.
Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Earnings Working Against Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Share Price
